Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide

What Was Tested

This randomized controlled trial paper looks at Octreotide and Somatostatin.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

The primary end point was maintenance of biochemical control at the end of treatment (mean insulin-like growth factor 1 [IGF-1] ≤ 1.0 × upper limit of normal [ULN]; weeks 34 and 36).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Octreotide group and the comparison group should start out alike.

As a double-blind Octreotide study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Octreotide, giving a reference point.

Time to loss of IGF-1 response and proportion requiring reversion to injectable SRLs were assessed as broader control measures.

What Was Measured

PubMed files the paper under topics including Acromegaly, Drug Substitution, Human Growth Hormone, Injections, Insulin-Like Growth Factor I, Octreotide and Somatostatin.

Author keywords: oral octreotide, IGF-1, somatostatin analogues and somatostatin receptor ligands.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Octreotide and Somatostatin.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.